The rapid spread of SARS-COV-2 Omicron variant in Italy reflected early through wastewater surveillance

Rosa, Giuseppina La; Iaconelli, Marcello; Veneri, Carolina; Mancini, Pamela; Ferraro, Giusy Bonanno; Brandtner, David; Lucentini, Luca; Bonadonna, Lucia; Rossi, Mirko; Grigioni, Mauro; Suffredini, Elisabetta

doi:10.1016/j.scitotenv.2022.155767

Cited by 45 publications

(25 citation statements)

References 17 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The constantly evolving epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [ 4 ], the diffusion of new viral variants (more recently, the B.1.1.529 Variant of Concern (named Omicron) and descendent lineages [ 5 ]), and the waning of protection offered by vaccination over time [ 6 , 7 ] has impacted the SARS-CoV-2 transmissibility, the occurrence of breakthrough infections and the COVID-19 vaccine effectiveness, with the need for boosting immunity to ensure continuity of protection [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Risk of Repeated Adverse Effects following Booster Dose of mRNA COVID-19 Vaccine: Results from the MOSAICO Study

et al. 2023

View full text Add to dashboard Cite

The successful deployment of safe and effective vaccines against coronavirus disease 2019 (COVID-19) has been crucial in reducing the global disease burden. Owing to the need for vaccination series over time, continuous observational studies are needed to estimate the COVID-19 vaccine response in real-world conditions. In particular, the detection, assessment, and understanding of adverse effects following immunization (AEFI) with a COVID-19 vaccine are crucial to better address vaccination strategies. Therefore, this study aimed to investigate the risk of repeated AEFI post-administration of a booster dose of mRNA COVID-19 vaccine in a sample of healthcare workers (HCWs) in an Italian teaching hospital. The data on any local and systemic AEFI were studied in multivariate Poisson regression analyses to model the association between the incidence of each postvaccination symptom and its prior reporting after the administration of the previous doses. Overall, compared with the primary vaccination series, the majority of post-third dose AEFI were less reported. The results from multivariable models showed that the likelihood of reporting an AEFI after the third dose was higher in those who experienced the same postvaccination symptom after the second dose (all AEFI except for itch at injection site) and, although not significant for all AEFI, after the first dose. Any associations with age, gender, smoking habits, previous SARS-CoV-2 infection and other characteristics, as well as the health impact of AEFI were also assessed. Taken together, the results from this research support reframe AEFI symptoms as signals of a robust postvaccination reaction as well as of common vaccine response, and they add important data to inform booster vaccination strategies in HCWs and, extensively, in the adult population.

show abstract

Section: Introductionmentioning

confidence: 99%

Risk of Repeated Adverse Effects following Booster Dose of mRNA COVID-19 Vaccine: Results from the MOSAICO Study

et al. 2023

View full text Add to dashboard Cite

show abstract

“…We validate both this Omicron- and a Delta variant specific assay ( Lee et al, 2021a , 2022 ) in influent samples collected from a WWTP in Italy over a duration of 10 months (April 2021-January 2022). While similar RT-qPCR assays have been developed and applied for Omicron in Italy, it remains a challenge to derive accurate variant trends, in part due to potential assay cross-reactivity against other SARS-CoV-2 variants ( Cutrupi et al, 2022 ; La Rosa et al, 2022 ). Here we show that our assays were able to provide, through wastewater testing, quantitatively accurate trends and reveal variant displacement dynamics that concur with clinical observations.…”

Section: Introductionmentioning

confidence: 99%

Rapid displacement of SARS-CoV-2 variant Delta by Omicron revealed by allele-specific PCR in wastewater

et al. 2022

View full text Add to dashboard Cite

“… 70 Similarly, the Sewage analysis CORe group–Europe (SCORE) network performs quantitative annual monitoring for consumption of a range of different illicit substances across Europe, allowing both temporal and geographical patterns to be assessed. 71 In contrast, in surveillance for infectious disease (e.g., WBE for COVID-19 during the early stages of the pandemic, 72 , 73 monitoring for new variants of concern 74 ) or suspect screening for NPS, 75 qualitative data may be sufficient. In addition, for some biomarkers it may not be possible to obtain accurate quantitative information.…”

Section: Discussionmentioning

confidence: 99%

A Framework for Public Health Authorities to Evaluate Health Determinants for Wastewater-Based Epidemiology

Eaton

Coxon

Pattis

et al. 2022

Environ Health Perspect

View full text Add to dashboard Cite

Background: Wastewater-based epidemiology (WBE) is rapidly developing as a powerful public health tool. It can provide information about a wide range of health determinants (HDs), including community exposure to environmental hazards, trends in consumption of licit and illicit substances, spread of infectious diseases, and general community health. As such, the list of possible candidate HDs for WBE is almost limitless. Consequently, a means to evaluate and prioritize suitable candidates for WBE is useful, particularly for public health authorities, who often face resource constraints. Objectives: We have developed a framework to assist public health authorities to decide what HDs may be appropriate for WBE and what biomarkers could be used. This commentary reflects the experience of the authors, who work at the interface of research and public health implementation. Discussion: To be suitable for WBE, a candidate HD should address a public health or scientific issue that would benefit from better understanding at the population level. For HDs where information on individual exposures or stratification by population subgroups is required, WBE is less suitable. Where other methodologies are already used to monitor the candidate HD, consideration must be given to whether WBE could provide better or complementary information to the current approach. An essential requirement of WBE is a biomarker specific for the candidate HD. A biomarker in this context refers to any human-excreted chemical or biological that could act as an indicator of consumption or exposure to an environmental hazard or of the human health state. Suitable biomarkers should meet several criteria outlined in this commentary, which requires background knowledge for both the biomarker and the HD. An evaluation tree summarizing key considerations for public health authorities when assessing the suitability of candidate HDs for WBE and an example evaluation are presented. https://doi.org/10.1289/EHP11115

show abstract

The rapid spread of SARS-COV-2 Omicron variant in Italy reflected early through wastewater surveillance

Cited by 45 publications

References 17 publications

Risk of Repeated Adverse Effects following Booster Dose of mRNA COVID-19 Vaccine: Results from the MOSAICO Study

Risk of Repeated Adverse Effects following Booster Dose of mRNA COVID-19 Vaccine: Results from the MOSAICO Study

Rapid displacement of SARS-CoV-2 variant Delta by Omicron revealed by allele-specific PCR in wastewater

A Framework for Public Health Authorities to Evaluate Health Determinants for Wastewater-Based Epidemiology

Contact Info

Product

Resources

About